🚀 VC round data is live in beta, check it out!
Huadong Medicine Valuation Multiples
Discover revenue and EBITDA valuation multiples for Huadong Medicine and similar public comparables like Vaxcyte, Krka, Eisai Co., Aurobindo Pharma and more.
Huadong Medicine Overview
About Huadong Medicine
Huadong Medicine Co Ltd is engaged in the production and sales of antibiotics, proprietary Chinese medicine, chemical synthetic medicine, and genetic engineering drug products. The company mainly operates its business through three segments. The Manufacturing Business segment is engaged in the research and development, production, and marketing of specialized medicines, medicines for chronic diseases, as well as special medicines. The Commercial Business segment is engaged in the sales of medicines, medical devices, ginseng, and antler pieces. The International Medical Beauty Business segment is engaged in the production and sales of regeneration products, hyaluronic acids, and botulinum toxin products.
Founded
1993
HQ
Employees
18.3K
Website
Sectors
Financials (LTM)
EV
$9B
Huadong Medicine Financials
Huadong Medicine reported last 12-month revenue of $7B and EBITDA of $852M.
In the same LTM period, Huadong Medicine generated $2B in gross profit, $852M in EBITDA, and $582M in net income.
Revenue (LTM)
Huadong Medicine P&L
In the most recent fiscal year, Huadong Medicine reported revenue of $6B and EBITDA of $770M.
Huadong Medicine expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $7B | XXX | $6B | XXX | XXX | XXX |
| Gross Profit | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Margin | 32% | XXX | 33% | XXX | XXX | XXX |
| EBITDA | $852M | XXX | $770M | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 13% | XXX | XXX | XXX |
| EBIT Margin | 11% | XXX | 11% | XXX | XXX | XXX |
| Net Profit | $582M | XXX | $515M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | 8% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Huadong Medicine Stock Performance
Huadong Medicine has current market cap of $9B, and enterprise value of $9B.
Market Cap Evolution
Huadong Medicine's stock price is $5.05.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9B | $9B | -2.4% | XXX | XXX | XXX | $0.29 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialHuadong Medicine Valuation Multiples
Huadong Medicine trades at 1.3x EV/Revenue multiple, and 10.0x EV/EBITDA.
EV / Revenue (LTM)
Huadong Medicine Financial Valuation Multiples
As of April 18, 2026, Huadong Medicine has market cap of $9B and EV of $9B.
Equity research analysts estimate Huadong Medicine's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Huadong Medicine has a P/E ratio of 15.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9B | XXX | $9B | XXX | XXX | XXX |
| EV (current) | $9B | XXX | $9B | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | 10.0x | XXX | 11.1x | XXX | XXX | XXX |
| EV/EBIT | 11.9x | XXX | 12.6x | XXX | XXX | XXX |
| EV/Gross Profit | 4.0x | XXX | 4.2x | XXX | XXX | XXX |
| P/E | 15.2x | XXX | 17.2x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 28.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Huadong Medicine Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Huadong Medicine Margins & Growth Rates
Huadong Medicine's revenue in the last 12 month grew by 7%.
Huadong Medicine's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Huadong Medicine's rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Huadong Medicine's rule of X is 33% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Huadong Medicine Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 7% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 21% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 33% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 16% | XXX | 14% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | 4% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 22% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Huadong Medicine Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Huadong Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Vaxcyte | XXX | XXX | XXX | XXX | XXX | XXX |
| Krka | XXX | XXX | XXX | XXX | XXX | XXX |
| Eisai Co. | XXX | XXX | XXX | XXX | XXX | XXX |
| Aurobindo Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Haisco Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Huadong Medicine M&A Activity
Huadong Medicine acquired XXX companies to date.
Last acquisition by Huadong Medicine was on XXXXXXXX, XXXXX. Huadong Medicine acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Huadong Medicine
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialHuadong Medicine Investment Activity
Huadong Medicine invested in XXX companies to date.
Huadong Medicine made its latest investment on XXXXXXXX, XXXXX. Huadong Medicine invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Huadong Medicine
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Huadong Medicine
| When was Huadong Medicine founded? | Huadong Medicine was founded in 1993. |
| Where is Huadong Medicine headquartered? | Huadong Medicine is headquartered in China. |
| How many employees does Huadong Medicine have? | As of today, Huadong Medicine has over 18K employees. |
| Is Huadong Medicine publicly listed? | Yes, Huadong Medicine is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Huadong Medicine? | Huadong Medicine trades under 000963 ticker. |
| When did Huadong Medicine go public? | Huadong Medicine went public in 2000. |
| Who are competitors of Huadong Medicine? | Huadong Medicine main competitors are Vaxcyte, Krka, Eisai Co., Aurobindo Pharma. |
| What is the current market cap of Huadong Medicine? | Huadong Medicine's current market cap is $9B. |
| What is the current revenue of Huadong Medicine? | Huadong Medicine's last 12 months revenue is $7B. |
| What is the current revenue growth of Huadong Medicine? | Huadong Medicine revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Huadong Medicine? | Current revenue multiple of Huadong Medicine is 1.3x. |
| Is Huadong Medicine profitable? | Yes, Huadong Medicine is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Huadong Medicine? | Huadong Medicine's last 12 months EBITDA is $852M. |
| What is Huadong Medicine's EBITDA margin? | Huadong Medicine's last 12 months EBITDA margin is 13%. |
| What is the current EV/EBITDA multiple of Huadong Medicine? | Current EBITDA multiple of Huadong Medicine is 10.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.